by Elena Iemma | Dec 9, 2024 | News
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by...
